Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History
International Journal of Gastroenterology Disorders & Therapy Volume 4 (2017), Article ID 4:IJGDT-129, 6 pages
https://doi.org/10.15344/2393-8498/2017/129
Research Article
A Potential Asset of Proteasome Inhibitor Singly or Combined with Cisplatin Provides Inhibitory Effect on Human Gastric Cancer Cells

Jie Jin1, Zhenzhen Li2, Honghua Ding2 and Dadao Jing2,*

1Department of Gastroenterology, Branch of Shanghai General Hospital, Shanghai, China
2Department of Geriatrics and Gastroenterology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China
Dr. Dadao Jing, Department of Geriatrics and Gastroenterology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China; E-mail: dadaojing@126.com
17 February 2017; 09 August 2017; 11 August 2017
Jin J, Li Z, Ding H, Jing D (2017) A Potential Asset of Proteasome Inhibitor Singly or Combined with Cisplatin Provides Inhibitory Effect on Human Gastric Cancer Cells. Int J Gastroenterol Disord Ther 4: 129. doi: http://dx.doi.org/10.15344/2393-8498/2017/129
© 2017 Jin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

  1. Elliott PJ, Ross JS (2001) The proteasome: a new target for novel drug therapies. Am J Clin Pathol 116: 637-646. View
  2. Naujokat C, Fuchs D, Berges C (2007) Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition. Biochim Biophys Acta 1773: 1389-1397. View
  3. Redzic JS, Gomez JD, Hellwinkel JE, Anchordoquy TJ, Graner MW (2016) Proteomic analyses of brain tumor cell lines amidst the unfolded protein response. Oncotarget 267: 47831-47847. View
  4. Yang P, Li ZY, Li HQ (2015) Potential Roles of Protease inhibitors in cancer progression . Asian Pac J Cancer Prev16: 8047-8052. View
  5. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP (2011) Bortezomibas the first proteasome inhibitor anticancerdrug: current status and future perspectives. Curr Cancer Drug Targets 11: 239-253. View
  6. Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, et al. (2013) U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 19: 4559-4563. View
  7. Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, et al. (2009) Phase I study of vorinostat in combination withbortezomibfor relapsed and refractory multiple myeloma. Clin Cancer Res 15: 5250-5257. View
  8. Turkington RC, Purcell C, James CR, Millar J, Napier E, et al. (2014) Aphase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma. Invest New Drugs 32: 250-260. View
  9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917. View
  10. Wright JJ (2010) Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 16: 4094-4104. View
  11. Ma Y, Chen B, Liu D, Yang Y , Xiong Z, et al. (2011) MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-kB/TGFb1 pathway. Biochem Pharmacol 81: 1228-1236. View
  12. Guo N, Peng Z (2013) MG132, a proteasome inhibitor, induces a poptosis in tumor cells. Asia Pac J Clin Oncol 9: 6-11. View
  13. Fan WH, Hou Y, Meng FK, Wang XF, Luo YN, et al. (2011) Proteasome inhibitor MG-132inducesC6 glioma cellapoptosisvia oxidative stress. Acta Pharmacol Sin 32: 619-625. View
  14. Dou QP, Zonder JA (2014) Overview of proteasome inhibitor-based anticancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitinproteasome system. Curr Cancer Drug Targets 14: 517-536. View
  15. Mujtaba T, Dou Q (2011) Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 12: 471-480. View
  16. Fostier K, De Becker A, Schots R (2012) Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. Onco Targets Ther 5: 237. View
  17. Kisselev AF, van der Linden WA, Overkleeft HS (2012) Proteasome inhibitors:an expanding army attacking a unique target. Chem Biol 19: 99- 115. View
  18. Panischeva LA, Kakpakova ES, Rybalkina EY, Stavrovskaya AA (2011) Influence of proteasome inhibitor bortezomib on the expression of multidrug resistance genes and Akt kinase activity. Biochemistry (Mosc) 76: 1009-1016. View
  19. O'Grady S, Finn SP, Cuffe S, Richard DJ, O'Byrne KJ, et al. (2014) The role of DNA repair pathways in cisplatin resistant lung cancer. Cancer Treat Rev 40: 1161-1170. View
  20. Martin LP, Hamilton TC, Schilder RJ (2008) Platinumresistance: the role of DNA repair pathways. Clin Cancer Res 14: 1291-1295. View
  21. Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, et al. (2007) ERCC1genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinumbased therapy. J Clin Oncol 25: 5172-5179. View
  22. Li W, Jie Z, Li Z, Liu Y, Gan Q, Mao Y, et al. (2014) ERCC1siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines. Mol Med Rep 9: 2423-2428. View
  23. Ueda S, Shirabe K, Morita K, Umeda K, Kayashima H, et al. (2011) Evaluation of ERCC1expression for cisplatin sensitivity in human hepatocellular carcinoma. Ann Surg Oncol 18: 1204-1211. View
  24. Li Y, Gao H, Wang Y, Dai C (2015) Investigation the mechanism of the apoptosis induced by lactacystin in gastric cancer cells. Tumour Biol 36: 3465-3470. View
  25. Mimnaugh EG, Yunmbam MK, Li Q, Bonvini P, Hwang SG, et al. (2000) Prevention of cisplatin-DNA adduct repair and potentiation of cisplatininduced apoptosis inovariancarcinoma cells by proteasome inhibitors. Biochem Pharmacol 60: 1343-1354. View
  26. Tsuburaya A, Sugimoto N, Imamura H, Nishikawa K, Imamoto H, et al. (2016) Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/ TOP-002). Clin Oncol (R Coll Radiol) 28: e45-51. View
  27. Wang J, Zhou XQ, Li JY, Cheng JF, Zeng XN, et al. (2014) Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer. Chine J Cancer Res 26: 323-330. View
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2024 Graphy Publications, All Rights Reserved.